Search clinical trials for: Buprenorphine Extended-Release Injection

Total 1068 results

New York State Psychiatric Institute

Completed

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

Opioid-use Disorder

United States
Indivior Inc.

Completed

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Opioid Use Disorder

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Withdrawn

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Opioid Use Disorder

United States
Royal Victoria Hospital, Canada

Not yet recruiting

Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (STOPIT)

Moderate to Severe Opioid Use Disorder

Canada
Yih-Ing Hser
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Not yet recruiting

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (RXR)

Substance-Related Disorders | Opioid-Related Disorders | Narcotic-Related Disorders

United States
Friends Research Institute, Inc.

Recruiting

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Opioid-use Disorder

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Suspended

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Opioid-use Disorder

United States
NYU Langone Health
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Opioid Use Disorder (OUD)

United States
Friends Research Institute, Inc.

Not yet recruiting

Buprenorphine for Individuals in Jail

Opioid Use Disorder

United States
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Study

Opioid-use Disorder

United States
Indivior Inc.

Active, not recruiting

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Moderate to Severe Opioid-use Disorder

United States, Canada
Indivior Inc.

Completed

Open-Label Treatment Extension Study

Opioid Use Disorder | Opioid-related Disorders

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Extension Study

Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Assessing Optimal XRB Initiation Points in Jail

Opioid Use Disorder

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
NYU Langone Health
NYC Health + Hospitals

Completed

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Opioid Dependence

United States
Wake Forest University Health Sciences

Withdrawn

Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

Opioid Use
Murdoch Childrens Research Institute

Recruiting

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) (MARVEL-PIC)

Neoplasms | Bone Marrow Transplantation

Australia
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
University of California, Los Angeles
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Cocaine Use Reduction With Buprenorphine (CURB)

Cocaine Dependence

United States
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Unknown

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
LG Life Sciences

Completed

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Healthy

Korea, Republic of
Paolo Mannelli
Alkermes, Inc.

Completed

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (BUP/NXT-VIVI)

Opiate Dependence

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (CURB-2)

Cocaine Use Disorder

United States
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
Chemi S.p.A.

Completed

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Seroma

Italy
Braeburn Pharmaceuticals

Completed

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Opioid Use Disorders

United States
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States

Search clinical trials for: Buprenorphine Extended-Release Injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations